Suppr超能文献

HIV-1 群特异性抗原加工中间体以反式显性方式干扰HIV-1的感染性。

HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.

作者信息

Müller Barbara, Anders Maria, Akiyama Hisashi, Welsch Sonja, Glass Bärbel, Nikovics Krisztina, Clavel Francois, Tervo Hanna-Mari, Keppler Oliver T, Kräusslich Hans-Georg

机构信息

Department of Virology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany.

出版信息

J Biol Chem. 2009 Oct 23;284(43):29692-703. doi: 10.1074/jbc.M109.027144. Epub 2009 Aug 7.

Abstract

Protease inhibitors (PI) act by blocking human immunodeficiency virus (HIV) polyprotein processing, but there is no direct quantitative correlation between the degree of impairment of Gag processing and virion infectivity at low PI concentrations. To analyze the consequences of partial processing, virus particles were produced in the presence of limiting PI concentrations or by co-transfection of wild-type proviral plasmids with constructs carrying mutations in one or more cleavage sites. Low PI concentrations caused subtle changes in polyprotein processing associated with a pronounced reduction of particle infectivity. Dissection of individual stages of viral entry indicated a block in accumulation of reverse transcriptase products, whereas virus entry, enzymatic reverse transcriptase activity, and replication steps following reverse transcription were not affected. Co-expression of low amounts of partially processed forms of Gag together with wild-type HIV generally exerted a trans-dominant effect, which was most prominent for a construct carrying mutations at both cleavage sites flanking the CA domain. Interestingly, co-expression of low amounts of Gag mutated at the CA-SP1 cleavage site also affected processing activity at this site in the wild-type virus. The results indicate that low amounts (<5%) of Gag processing intermediates can display a trans-dominant effect on HIV particle maturation, with the maturation cleavage between CA and SP1 being of particular importance. These effects are likely to be important for the strong activity of PI at concentrations achieved in vivo and also bear relevance for the mechanism of action of the antiviral drug bevirimat.

摘要

蛋白酶抑制剂(PI)通过阻断人类免疫缺陷病毒(HIV)多聚蛋白的加工发挥作用,但在低PI浓度下,Gag加工受损程度与病毒体感染性之间没有直接的定量相关性。为了分析部分加工的后果,在有限的PI浓度存在下产生病毒颗粒,或者通过将野生型前病毒质粒与携带一个或多个切割位点突变的构建体共转染来产生病毒颗粒。低PI浓度导致多聚蛋白加工发生细微变化,同时伴随着颗粒感染性的显著降低。对病毒进入的各个阶段进行剖析表明,逆转录酶产物的积累受到阻碍,而病毒进入、酶促逆转录酶活性以及逆转录后的复制步骤均未受到影响。低量的部分加工形式的Gag与野生型HIV共同表达通常会产生反式显性效应,对于在CA结构域两侧的两个切割位点均携带突变的构建体而言,这种效应最为显著。有趣的是,在CA - SP1切割位点发生突变的低量Gag的共同表达也会影响野生型病毒中该位点的加工活性。结果表明,低量(<5%)的Gag加工中间体可对HIV颗粒成熟产生反式显性效应,其中CA和SP1之间的成熟切割尤为重要。这些效应可能对于PI在体内达到的浓度下的强大活性很重要,并且也与抗病毒药物贝维拉马的作用机制相关。

相似文献

1
HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.
J Biol Chem. 2009 Oct 23;284(43):29692-703. doi: 10.1074/jbc.M109.027144. Epub 2009 Aug 7.
3
Resistance to Second-Generation HIV-1 Maturation Inhibitors.
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.02017-18. Print 2019 Mar 15.
4
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
Virology. 2010 Apr 25;400(1):137-44. doi: 10.1016/j.virol.2010.01.028. Epub 2010 Feb 20.
6
Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles.
Proc Natl Acad Sci U S A. 2020 May 12;117(19):10286-10293. doi: 10.1073/pnas.1917755117. Epub 2020 Apr 27.
7
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
PLoS Pathog. 2016 Nov 28;12(11):e1005990. doi: 10.1371/journal.ppat.1005990. eCollection 2016 Nov.
8
HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice.
J Virol. 2011 Feb;85(4):1420-8. doi: 10.1128/JVI.01926-10. Epub 2010 Nov 24.
9
Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15. Print 2016 Jan.

引用本文的文献

1
Structural maturation of the matrix lattice is not required for HIV-1 particle infectivity.
Sci Adv. 2025 May 9;11(19):eadv4356. doi: 10.1126/sciadv.adv4356.
2
The conserved HIV-1 spacer peptide 2 triggers matrix lattice maturation.
Nature. 2025 Apr;640(8057):258-264. doi: 10.1038/s41586-025-08624-9. Epub 2025 Feb 26.
3
The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery.
J Biol Chem. 2025 Jan;301(1):108079. doi: 10.1016/j.jbc.2024.108079. Epub 2024 Dec 14.
4
The conserved HIV-1 spacer peptide 2 triggers matrix lattice maturation.
bioRxiv. 2024 Nov 6:2024.11.06.622200. doi: 10.1101/2024.11.06.622200.
5
Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937.
Viruses. 2024 Sep 24;16(10):1508. doi: 10.3390/v16101508.
7
Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability.
ACS Med Chem Lett. 2023 Jul 11;14(8):1021-1030. doi: 10.1021/acsmedchemlett.3c00279. eCollection 2023 Aug 10.
8
Neutral sphingomyelinase 2 is required for HIV-1 maturation.
Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2219475120. doi: 10.1073/pnas.2219475120. Epub 2023 Jul 5.

本文引用的文献

4
Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis.
Cell Host Microbe. 2008 Dec 11;4(6):592-9. doi: 10.1016/j.chom.2008.10.013.
5
Viral protease inhibitors.
Handb Exp Pharmacol. 2009;189(189):85-110. doi: 10.1007/978-3-540-79086-0_4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验